Research Reports - Short-term efficacy and tolerability of methylphenidate in children with traumatic brain injury and attention problems
Brain Dev. 2016 Nov 28. pii: S0387-7604(16)30190-5. doi:
10.1016/j.braindev.2016.11.005. [Epub ahead of print]
Ekinci O(1), Direk MÇ(2), Gunes S(3), Teke H(3), Ekinci N(3), Yıldırım F(3),
PURPOSE: This study aims to investigate the short-term efficacy and tolerability
of immediate-release methylphenidate (IR-MPH) in children with a history of
traumatic brain injury (TBI).
METHODS: Twenty children with TBI (mean age: 12.7±3.1years) who had clinically
significant attention deficit and/or hyperactivity-impulsivity symptoms and
twenty children with primary Attention Deficit Hyperactivity Disorder (ADHD)
(mean age: 12.3±3.05years) were included. Study measures, which included the
Turgay DSM-IV based ADHD rating Scale (T-DSM-IV-S), Conners' Parent Rating Scale
(CPRS), Conners' Teacher Rating Scale (CTRS-R) and Clinical Global
Impression-Improvement Scale (CGI-I), were completed at the baseline for both of
the groups. For the TBI group, study measures and an adverse effect scale
developed by the authors were completed 8weeks after IR-MPH treatment (10mg dose
RESULTS: No significant difference was found regarding the baseline scale scores
between the study groups. Among children with TBI, most of the scores on
T-DSM-IV-S, CPRS and CTRS-R were found to improve significantly after MPH
treatment, (p<0.05). 70% (N=14) of the sample were much improved at the endpoint.
MPH was generally well-tolerated (95% had either no adverse effect or mild
CONCLUSION: In this preliminary open-label study, IR-MPH was found as a safe and
effective treatment option for ADHD symptoms after TBI. However, future
controlled studies are needed to confirm our findings.